Stockhammer, Florian

[["dc.bibliographiccitation.firstpage","2093"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Anticancer Research"],["dc.bibliographiccitation.lastpage","2098"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Misch, Martin"],["dc.contributor.author","Czabanka, Marcus"],["dc.contributor.author","Dengler, Julius"],["dc.contributor.author","Stoffels, Mandy"],["dc.contributor.author","Auf, Gregor"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Stockhammer, Florian"],["dc.date.accessioned","2018-11-07T09:25:01Z"],["dc.date.available","2018-11-07T09:25:01Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: The major side-effects of bevacizumab in glioma treatment are venous thromboembolic events (VTE). We retrospectively evaluated factors potentially predictive of thromboembolic events. Patients and Methods: Bevacizumab, alone or in combination with chemotherapy was used as salvage therapy for recurrence in malignant glioma every two weeks. None but one patient received anticoagulants. Before each bevacizumab cycle differential blood cell count, kidney and liver parameters, D-dimers, neurological status, body-mass index, vital signs and signs of venous thrombosis were assessed. Results: Thirty-eight patients received 428 cycles of bevacizumab. In five patients (13%), six VTE were observed. These complications were preceded four weeks before the onset of symptoms by D-dimer elevation above 0.865 mg/l [p<0.0001; sensitivity=89% (95% confidence interval=83-93%); specificity=89% (95% CI=52-100%)]. An existing hemiparesis constituted a 27-fold risk elevation for thrombotic complication (p<0.0001, chi(2)-test). Conclusion: D-Dimer elevation or hemiparesis predict VTE under bevacizumab and chemotherapy, four weeks before the event becomes clinically apparent. Future investigations should determine if prophylactic anti-coagulants for patients at risk may reduce the risk of VTE."],["dc.identifier.isi","000319233100039"],["dc.identifier.pmid","23645760"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29972"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Int Inst Anticancer Research"],["dc.relation.issn","0250-7005"],["dc.title","D-Dimer Elevation and Paresis Predict Thromboembolic Events During Bevacizumab Therapy for Recurrent Malignant Glioma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","407"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Translational Stroke Research"],["dc.bibliographiccitation.lastpage","414"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Malinova, Vesna"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Atangana, Etienne Ndzie"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","Rohde, Veit"],["dc.date.accessioned","2018-11-07T09:39:47Z"],["dc.date.available","2018-11-07T09:39:47Z"],["dc.date.issued","2014"],["dc.description.abstract","The optimal management of spontaneous intracerebral hemorrhage (ICH), especially if deep-seated, remains a matter of discussion. Lysis of the blood clot applying recombinant tissue-type plasminogen activator (rtPA) by an intrahematomal catheter is a minimally invasive treatment option, currently being under investigation in a randomized trial. The center position of the catheter in the hematoma is believed to be crucial for an optimal clot lysis. To achieve this objective, frame-based stereotaxy and frameless stereotaxy with guidance of an articulated arm were used. Recently, a preregistered stylet for direct navigation, alleviating the need of guidance, became available. In this study, we evaluated the relative error (RE) describing the deviation of the catheter from the ideal center position in the clot and compared the accuracy of catheter placement using frameless stereotaxy or the novel preregistered stylet. The intrahematomal catheter position was evaluated in three dimensions in 89 patients with spontaneous supratentorial ICH. Frameless stereotaxy with guidance of an articulated arm was performed in 50 patients. The preregistered stylet was used in 39 patients. The catheter position was evaluated using a RE calculating the distance perpendicular to the center of the catheter in relation to the hematoma's diameter. The mean hematoma volume was 51.4 ml. Forty-four out of 89 hematomas were deep-seated. Intraventricular blood was found in 59 patients. The RE of the catheter position was lower in the stylet group in comparison to the frameless stereotaxy group (mean 0.57 vs. 0.90; p = 0.0018). There was no difference between deep-seated and lobar hematomas with regard to the accuracy of catheter placement (p = 0.62). The RE is a robust measure for describing intrahematomal catheter position. The preregistered stylet facilitates a satisfactory catheter placement and is a viable alternative to frameless stereotaxy and guidance with the articulated arm."],["dc.identifier.doi","10.1007/s12975-014-0326-1"],["dc.identifier.isi","000336336200011"],["dc.identifier.pmid","24470086"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33363"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1868-601X"],["dc.relation.issn","1868-4483"],["dc.title","Catheter Placement for Lysis of Spontaneous Intracerebral Hematomas: Is a Navigated Stylet Better Than Pointer-Guided Frameless Stereotaxy for Intrahematomal Catheter Positioning?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1819"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Acta Neurochirurgica"],["dc.bibliographiccitation.lastpage","1823"],["dc.bibliographiccitation.volume","157"],["dc.contributor.author","Schatlo, Bawarjan"],["dc.contributor.author","Martinez, Ramon"],["dc.contributor.author","Alaid, Awad"],["dc.contributor.author","von Eckardstein, Kajetan L."],["dc.contributor.author","Akhavan-Sigari, Reza"],["dc.contributor.author","Hahn, Anselm W."],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Rohde, Veit"],["dc.date.accessioned","2018-11-07T09:51:13Z"],["dc.date.available","2018-11-07T09:51:13Z"],["dc.date.issued","2015"],["dc.description.abstract","Robotic assistance for the placement of pedicle screws has been established as a safe technique. Nonetheless rare instances of screw misplacement have been reported.The aim of the present retrospective study is to assess whether experience and time affect the accuracy of screws placed with the help of the SpineAssist (TM) robot system. Postoperative computed tomography (CT) scans of 258 patients requiring thoracolumbar pedicle screw instrumentation from 2008 to 2013 were reviewed. Overall, 13 surgeons performed the surgeries. A pedicle breach of > 3 mm was graded as a misplacement. Surgeons were dichotomised into an early and experienced period in increments of five surgeries. In 258 surgeries, 1,265 pedicle screws were placed with the aid of the robot system. Overall, 1,217 screws (96.2 %) were graded as acceptable. When displayed by surgeon, the development of percent misplacement rates peaked between 5 and 25 surgeries in 12 of 13 surgeons. The overall misplacement rate in the first five surgeries was 2.4 % (6/245). The misplacement rate rose to 6.3 % between 11 and 15 surgeries (10/158; p = 0.20), and reached a significant peak between 16 and 20 surgeries with a rate of 7.1 % (8/112; p = 0.03). Afterwards, misplacement rates declined. A major peak in screw inaccuracies occurred between cases 10 and 20, and a second, smaller one at about 40 surgeries. One potential explanation could be a transition from decreased supervision (unskilled but aware) to increased confidence of a surgeon (unskilled but unaware) who adopts this new technique prior to mastering it (skilled). We therefore advocate ensuring competent supervision for new surgeons at least during the first 25 procedures of robotic spine surgery to optimise the accuracy of robot-assisted pedicle screws."],["dc.identifier.doi","10.1007/s00701-015-2535-0"],["dc.identifier.isi","000361389600031"],["dc.identifier.pmid","26287268"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35872"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0942-0940"],["dc.relation.issn","0001-6268"],["dc.title","Unskilled unawareness and the learning curve in robotic spine surgery"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","761"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Acta Neurochirurgica"],["dc.bibliographiccitation.lastpage","765"],["dc.bibliographiccitation.volume","156"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Miethke, Christoph"],["dc.contributor.author","Knitter, Thoralf"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Sprung, Christian"],["dc.date.accessioned","2018-11-07T09:42:11Z"],["dc.date.available","2018-11-07T09:42:11Z"],["dc.date.issued","2014"],["dc.description.abstract","Noise disturbance arising from the valve is a rare event of ventriculoperitoneal shunts. We queried and investigated shunt patients for occurrence and evaluated the possible factors related to noise development. Fifty ambulatory patients with implanted proGAV valve were investigated consecutively. Patients were asked for any noise arising from the shunt. In all cases, the valve was auscultated in sitting and upright position. The position of the gravitational unit (GU) was determined in respect to the Frankfurt horizontal plane (FHP) and in head reclination. Ten valves were perfused in vitro at different settings. One valve was opened for video documentation, and a frequency analysis of the noise was performed in nine valves. Eight percent (4/50) of the patients reported a noise arising from the valve only in upright position in combination with maximum head reclination, and immediately stopped when performing Vasalva's maneuver. In three out of four of these patients, the noise was also audible for the investigator (FS) with a prepared stethoscope. Patients complaining about a noise had a larger GU deviation from vertical during head reclination (median: -80 vs -43A degrees, p = 0.0007, t-test). A deviations threshold of less than -58.4A degrees excluding audible noise by a negative predictive value of 1 (95 % confidence interval [CI] 0.9 to 1.0). In an experimental setting, the noise came from vibrations of the ball in the cone of the adjustable unit and was restricted to a flow of at least 220 ml/h. The noise frequencies tended to be higher at higher opening pressures. Valve-related noise development may occur in patients with proGAV valves. This event could be prevented during shunt placement by avoiding posterior tilt of the gravitational unit, especially in patients with a good cervical mobility. The noise might indicate transient peak flows and was not associated with clinical or radiological signs of overdrainage."],["dc.identifier.doi","10.1007/s00701-013-1876-9"],["dc.identifier.isi","000333127200020"],["dc.identifier.pmid","24048819"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33899"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0942-0940"],["dc.relation.issn","0001-6268"],["dc.title","Flow-related noise in patients with ventriculoperitoneal shunt using gravitational adjustable valves"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","764"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","International Journal of Oncology"],["dc.bibliographiccitation.lastpage","772"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Xu, X."],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Schmitt, Anita"],["dc.contributor.author","Casalegno-Garduno, Rosaely"],["dc.contributor.author","Enders, Anne"],["dc.contributor.author","Mani, Jiju"],["dc.contributor.author","Classen, Carl Friedrich"],["dc.contributor.author","Linnebacher, Michael"],["dc.contributor.author","Freund, Mathias"],["dc.contributor.author","Schmitt, Michael"],["dc.date.accessioned","2018-11-07T09:13:15Z"],["dc.date.available","2018-11-07T09:13:15Z"],["dc.date.issued","2012"],["dc.description.abstract","The median survival of patients with glioblastoma multiforme (GBM) remains poor. Innovative immunotherapies with dendritic cell (DC) vaccination might be combined with standard temozolomide (TMZ) treatment. Here, we evaluated the influence of TMZ on the phenotype and function of DCs and CD8(+) T cells. DCs were generated from the peripheral blood of healthy volunteers (HVs) and GBM patients. DCs were analyzed by light microscopy and flow cytometry. Phagocytic activity was tested by FITC-dextran engulfment. Mixed lymphocyte peptide cultures were followed by enzyme-linked immunospot (ELISPOT) and flow cytometry assays. TMZ was added to DC and T cell cultures at concentrations up to 500 mu M. Mature DCs were generated from HVs and GBM patients. Cells displayed a typical DC morphology and a mature DC phenotype. Expression of CD209 was even higher in DCs generated from patients under therapy than from HVs (75.2 vs. 51.1%). In contrast, CD40 (1.1 vs. 13.5%) and BDCA4 (26.5 vs. 52.9%) were lower expressed in GBM patients at time of diagnosis. Immature DCs showed high phagocytic activity. Addition of TMZ at concentrations up to 50 mu M did neither impair the phenotype nor the function of DCs. In ELISPOT and flow cytometry assays, no impairment of CD8(+) T cell responses to viral antigens could be observed. Taken together, TMZ does not impair the function of either DCs or the CD8(+) T cells."],["dc.identifier.doi","10.3892/ijo.2011.1269"],["dc.identifier.isi","000300118200018"],["dc.identifier.pmid","22134728"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27130"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Spandidos Publ Ltd"],["dc.relation.issn","1019-6439"],["dc.title","Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8(+) T cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","252"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Neurosurgery"],["dc.bibliographiccitation.lastpage","262"],["dc.bibliographiccitation.volume","83"],["dc.contributor.author","Thomale, Ulrich-Wilhelm"],["dc.contributor.author","Schaumann, Andreas"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Giese, Henrik"],["dc.contributor.author","Schuster, Dhani"],["dc.contributor.author","Kästner, Stefanie"],["dc.contributor.author","Ahmadi, Sebastian A."],["dc.contributor.author","Polemikos, Manolis"],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Gölz, Leonie"],["dc.contributor.author","Lemcke, Johannes"],["dc.contributor.author","Hermann, Elvis"],["dc.contributor.author","Schuhmann, Martin"],["dc.contributor.author","Beez, Thomas"],["dc.contributor.author","Fritsch, Michael"],["dc.contributor.author","Orakcioglu, Berk"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Bohner, Georg"],["dc.date.accessioned","2018-10-10T07:14:06Z"],["dc.date.available","2018-10-10T07:14:06Z"],["dc.date.issued","2018-08-01"],["dc.description.abstract","Freehand ventricular catheter placement may represent limited accuracy for the surgeon's intent to achieve primary optimal catheter position.To investigate the accuracy of a ventricular catheter guide assisted by a simple mobile health application (mhealth app) in a multicenter, randomized, controlled, simple blinded study (GAVCA study). In total, 139 eligible patients were enrolled in 9 centers. Catheter placement was evaluated by 3 different components: number of ventricular cannulation attempts, a grading scale, and the anatomical position of the catheter tip. The primary endpoint was the rate of primary cannulation of grade I catheter position in the ipsilateral ventricle. The secondary endpoints were rate of intraventricular position of the catheter's perforations, early ventricular catheter failure, and complications. The primary endpoint was reached in 70% of the guided group vs 56.5% (freehand group; odds ratio 1.79, 95% confidence interval 0.89-3.61). The primary successful puncture rate was 100% vs 91.3% (P = .012). Catheter perforations were located completely inside the ventricle in 81.4% (guided group) and 65.2% (freehand group; odds ratio 2.34, 95% confidence interval 1.07-5.1). No differences occurred in early ventricular catheter failure, complication rate, duration of surgery, or hospital stay. The guided ventricular catheter application proved to be a safe and simple method. The primary endpoint revealed a nonsignificant improvement of optimal catheter placement among the groups. Long-term follow-up is necessary in order to evaluate differences in catheter survival among shunted patients."],["dc.fs.pkfprnr","44523"],["dc.identifier.doi","10.1093/neuros/nyx420"],["dc.identifier.fs","633504"],["dc.identifier.pmid","28973670"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15918"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1524-4040"],["dc.title","GAVCA Study: Randomized, Multicenter Trial to Evaluate the Quality of Ventricular Catheter Placement with a Mobile Health Assisted Guidance Technique"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","15"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Neuro-Oncology"],["dc.bibliographiccitation.lastpage","22"],["dc.bibliographiccitation.volume","109"],["dc.contributor.author","Ahmadi, Rezvan"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Becker, Natalia"],["dc.contributor.author","Hohlen, Katarina"],["dc.contributor.author","Misch, Martin"],["dc.contributor.author","Christians, Arne"],["dc.contributor.author","Dictus, Christine"],["dc.contributor.author","Herold-Mende, Christel"],["dc.contributor.author","Capper, David"],["dc.contributor.author","Unterberg, Andreas"],["dc.contributor.author","von Deimling, Andreas"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Hartmann, Christian"],["dc.date.accessioned","2018-11-07T09:07:48Z"],["dc.date.available","2018-11-07T09:07:48Z"],["dc.date.issued","2012"],["dc.description.abstract","Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) have been identified in approximately 70-80 % of astrocytomas and oligodendrogliomas of WHO grades II and III, and in secondary glioblastomas. In addition, a low incidence of IDH2 mutations has been detected in these tumors, and the occurence of IDH1 and IDH2 mutations is mutually exclusive. For patients with anaplastic gliomas and glioblastomas with IDH1 mutations, overall survival was significantly longer than for patients with wild-type tumours. However, the prognostic value of IDH1 in low-grade gliomas remains ambiguous. IDH1 codon 132 and IDH2 codon 172 mutation status were determined by direct sequencing for a retrospective series of 100 patients with histologically diagnosed Astrocytomas WHO Grad II (A II), and investigated for association with patient outcome. For the patient cohort analysed, median progression-free survival (PFS) was 44.6 months (95 %-CI 1.0-267.0), time to progression (median time to malignant progression (TtMP) was 74.9 months (95 %-CI 1.6-236.2), and median overall survival (OS) was 81.4 months (95 %-CI 5.5-274.8). IDH1 mutations were identified in 79 % of the patients. IDH2 mutations were not observed. Univariate and multivariate analysis revealed no association between IDH1 mutation status and PFS, TtMP, and OS. Furthermore, there were no significant differences regarding PFS, TtMP, and OS between patients with and without IDH1 mutations who did not receive adjuvant treatment. The prognostic value of IDH1 mutations in low-grade astrocytomas is rather low compared with that in high-grade gliomas."],["dc.identifier.doi","10.1007/s11060-012-0863-y"],["dc.identifier.isi","000306953100003"],["dc.identifier.pmid","22528790"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25885"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0167-594X"],["dc.title","No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","92"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.lastpage","102"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Hutterer, Markus"],["dc.contributor.author","Nowosielski, Martha"],["dc.contributor.author","Haybaeck, Johannes"],["dc.contributor.author","Embacher, Sabine"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Gotwald, Thaddaeus"],["dc.contributor.author","Holzner, Bernhard"],["dc.contributor.author","Capper, David"],["dc.contributor.author","Preusser, Matthias"],["dc.contributor.author","Marosi, Christine"],["dc.contributor.author","Oberndorfer, Stefan"],["dc.contributor.author","Moik, Martin"],["dc.contributor.author","Buchroithner, Johanna"],["dc.contributor.author","Seiz, Marcel"],["dc.contributor.author","Tuettenberg, Jochen"],["dc.contributor.author","Herrlinger, Ulrich"],["dc.contributor.author","Wick, Antje"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Stockhammer, Guenther"],["dc.date.accessioned","2018-11-07T09:46:59Z"],["dc.date.available","2018-11-07T09:46:59Z"],["dc.date.issued","2014"],["dc.description.abstract","Background. Due to the redundancy of molecular pathways simultaneously involved in glioblastoma growth and angiogenesis, therapeutic approaches intervening at multiple levels seem particularly appealing. This prospective, multicenter, single-arm phase II trial was designed to evaluate the antitumor activity of sunitinib, an oral small-molecule inhibitor of several receptor tyrosine kinases, in patients with first recurrence of primary glioblastoma using a continuous once-daily dosing regimen. Patients received a starting dose of sunitinib 37.5 mg, followed by a maintenance dose between 12.5 mg and 50 mg depending on drug tolerability. The primary endpoint was a 6-month progression-free survival (PFS) rate. Secondary endpoints included median PFS, overall survival (OS), safety/toxicity, quality of life, and translational studies on the expression of sunitinib target molecules. Forty participants were included in this study, and no objective responses were detected. PFS6 was 12.5, median PFS 2.2 months, and median OS 9.2 months. Five participants (12.5) showed prolonged stable disease 6 months with a median PFS of 16.0 months (range, 6.441.4 mo) and a median OS of 46.9 months (range, 21.249.2 mo) for this subgroup. c-KIT expression in vascular endothelial cells (n 14 participants) was associated with improved PFS. The most common toxicities were fatigue/asthenia, mucositis/dermatitis, dysesthesias, gastrointestinal symptoms, cognitive impairment, leukoctopenia, and thrombocytopenia. Two participants (5) terminated treatment due to toxicity. Continuous daily sunitinib showed minimal antiglioblastoma activity and substantial toxicity when given at higher doses. High endothelial c-KIT expression may define a subgroup of patients who will benefit from sunitinib treatment by achieving prolonged PFS."],["dc.identifier.doi","10.1093/neuonc/not161"],["dc.identifier.isi","000329135900012"],["dc.identifier.pmid","24311637"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35009"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.relation.issn","1523-5866"],["dc.relation.issn","1522-8517"],["dc.title","A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Roth, Patrick"],["dc.contributor.author","Wiestler, Benedikt"],["dc.contributor.author","Hartmann, Christian"],["dc.contributor.author","Hau, Peter"],["dc.contributor.author","Nakamura, Makoto"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Sabel, Michael"],["dc.contributor.author","Koeppen, Susanne"],["dc.contributor.author","Ketter, Ralf"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Eyupoglus, Ilker"],["dc.contributor.author","Kaendler, Stephen"],["dc.contributor.author","Kalff, Rolf"],["dc.contributor.author","Galldiks, Norbert"],["dc.contributor.author","Schmidt-Graf, Friederike"],["dc.contributor.author","von Deimling, Andreas"],["dc.contributor.author","Platten, Michael"],["dc.contributor.author","Reifenberger, Guido"],["dc.contributor.author","Weller, Michael"],["dc.date.accessioned","2018-11-07T09:57:08Z"],["dc.date.available","2018-11-07T09:57:08Z"],["dc.date.issued","2015"],["dc.identifier.isi","000358036900460"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37097"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","525"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Acta Neurochirurgica"],["dc.bibliographiccitation.lastpage","530"],["dc.bibliographiccitation.volume","157"],["dc.contributor.author","Clajus, Christin"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Rohde, Veit"],["dc.date.accessioned","2018-11-07T10:00:35Z"],["dc.date.available","2018-11-07T10:00:35Z"],["dc.date.issued","2015"],["dc.description.abstract","The intra- and postoperative management of accidental durotomy in operations of the lumbar spine is not standardized. It is the aim of our survey to obtain an overview on the current practice in neurosurgical departments in Germany. The used questionnaire consisted of three questions and could be answered within a few minutes by checking boxes. In September 2012, the questionnaire was sent to 149 German neurosurgical departments. In the following 4 weeks 109 replies (73.2 %) were received. Seventy-one neurosurgical departments (65.1 %) treat dural tears by a combination of methods, 28 (25.7 %) with suture alone, 7 (6.4 %) with fibrin-coated fleeces alone, 2 (1.8 %) with muscle patch alone and 1 (0.9 %) with fibrin glue alone. Sixty-six neurosurgical departments (60.5 %) decide on postoperative bed rest depending on the quality of the dural closure. Forty-three (39.5 %) neurosurgical departments do not rely on the quality of the dural closure for their postoperative management. In total, 72.5 % of the neurosurgical departments prescribe bed rest for 1-3 days, 1.8 % for more than 3 days, whereas 25.7 % allow immediate mobilization. Among German neurosurgeons, no consensus exists concerning the intra- and postoperative management of accidental durotomies in lumbar spine surgery. Despite not being proved to reduce the rate of cerebrospinal fluid fistulas, bed rest is frequently used. As bed rest prolongs the hospital stay with additional costs and has the potential of a higher rate of medical complications, a prospective multicenter trial is warranted."],["dc.identifier.doi","10.1007/s00701-014-2325-0"],["dc.identifier.isi","000350027700026"],["dc.identifier.pmid","25577453"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37836"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0942-0940"],["dc.relation.issn","0001-6268"],["dc.title","The intra- and postoperative management of accidental durotomy in lumbar spine surgery: results of a German survey"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]